ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0368 • ACR Convergence 2024

    Development and Validation of a Patient-centered Self-evaluation Questionnaire in Systemic Lupus Erythematosus: LUPIN®

    Marc Scherlinger1, Jean-Francois Kleinmann1, Antonin Folliasson2, Marianne Riviere3, Raphaelle Rybak4, Sabine Malivoir5, Jean-François Viallard6, Estibaliz Lazaro7, Christophe Richez8, Irene Machelart9, Nadine Magy-Bertrand10, Audrey Gorse11, Gilles Blaison12, Julien Campagne13, Benjamin Dervieux14, Thomas Moulinet15, Roland Jaussaud16, Pascal Roblot17, Mathieu Puyade17, Amélie Servettaz18, Pauline Orquevaux18, Julie le Scanff19, DANIEL WENDLING20, Marc Andre21, Ludovic Trefond21, Perrine SMETS22, Nicolas Baillet23, Christophe Deligny24, Xavier Mariette25, ARNAUD HOT26, Emmanuelle David27, Laurent Perard28, Estelle Jean29, Sarah Permal30, Denis WAHL31, Christian Agard32, François Chasset33, Baptiste Hervier34, Pasquer Ronan2, Mickael Martin17, Ludivine Lebourg35, Frederic Renou36, Loic Raffray36, Elisabeth Diot37, Cecile Fermont38, Thierry Martin39, Anne-Sophie Korganow39, Jacques-Eric Gottenberg40, Jean Sibilia41 and Zahir Amoura42, 1Strasbourg University Hospital - National reference center for autoimmune disease, Rheumatology, Strasbourg, France, 2Hometrix Health, Paris, France, 3Association Francaise du Lupus et autres maladies autoimmunes (AFL+), Metz, France, 4Association Francaise du Lupus et autres maladies autoimmunes (AFL+), Paris, France, 5APHP Pitié Salpêtrière - National reference center for autoimmune disease, Internal Medicine, Paris, France, 6CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FR, Bordeaux, France, 7Bordeaux University Hospital, Pessac, France, 8Université de Bordeaux, Bordeaux, France, 9CH de Bayonne - Competence center for autoimmune diseases, Internal Medicine, Bayonne, France, 10CHU de Besancon - Competence center for autoimmune diseases, Internal Medicine, Besançon, France, 11CH de Chambery - Competence center for autoimmune diseases, Internal Medicine, Chambery, France, 12CH de Colmar - Competence center for autoimmune diseases, Internal Medicine, Colmar, France, 13Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, 14CH de Mulhouse - Competence center for autoimmune diseases, Internal Medicine, Mulhouse, France, 15CHRU de Nancy, Vandœuvre-lès-Nancy, France, 16CHU de Nancy - Competence center for autoimmune diseases, Internal Medicine, Nancy, France, 17CHU de Poitiers - Competence center for autoimmune diseases, Internal Medicine, Poitiers, France, 18CHU de Reims - Competence center for autoimmune diseases, Internal Medicine, Reims, France, 19CH - Competence center for autoimmune diseases, Internal Medicine, Villefranche-sur-Saone, France, 20University Hospital, Besançon, France, 21CHU de Clermont-Ferrand - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, 22Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, 23CH de Basse-Terre - Competence center for autoimmune diseases, Internal Medicine, Basse-Terre, France, 24University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique, 25Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 26Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, 27HCL - Croix Rousse, Internal Medicine, Lyon, France, 28Hopital Saint-Joseph, Internal Medicine, Lyon, France, 29APHM - La Timone, Internal Medicine, Marseille, France, 30CH Mayotte - CH Wallis-et-Futuna, Internal Medicine, Mamoudzou, Mayotte, 31Lorraine University, Nancy, France, 32CHU de Nantes - National reference center for autoimmune disease, Internal Medicine, Nantes, France, 33Dermatology, Hôpital Tenon, Paris, France, 34APHP Saint-Louis - National reference center for autoimmune disease, Internal Medicine, Paris, France, 35CHU de Rouen, Internal Medicine, Rouen, France, 36CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, 37CHU de Tours - Competence center for autoimmune diseases, Internal Medicine, Tours, France, 38CH de Valence - Competence center for autoimmune diseases, Internal Medicine, Valence, France, 39Strasbourg University Hospital, National reference center for autoimmune disease, Clinical Immunology, Strasbourg, France, 40Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 41Strasbourg University Hospital, National reference center for autoimmune disease, Rheumatology, Strasbourg, France, 42French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France

    Background/Purpose: Systemic Lupus Erythematosus (SLE) features unpredictable disease activity fluctuations, making flare hard to detect and significantly impairing quality of life. This highlights the need…
  • Abstract Number: 0435 • ACR Convergence 2024

    Use of Contraception in Women of Childbearing Age with Immune-Mediated Rheumatic Diseases: Experience from an Italian Centre

    Clizia Gagliardi1, Maria Chiara Gerardi2, Eleonora Giacobbe3, Sara Benedetti2, Giuseppina Di Raimondo2, Assunta Ascione3, Monica Barichello2, Nicola Ughi4, Antonella Adinolfi2, Laura Belloli2, Cinzia Casu2, Maria Di Cicco2, Davide antonio Filippini2, Matteo Longhi2, Bianca Lucia Palermo2, Martina Schettino2, Giulia Segatto2, Elisa Verduci2 and Oscar Massimiliano Epis2, 1Niguarda Hospital, Milan, Bergamo, Italy, 2Niguarda Hospital, Milan, Milan, Italy, 3Niguarda Hospital, Milan, Milan, 4Niguarda Hospital, Milan, Mila, Italy

    Background/Purpose: Contraception is a relevant issue for women of childbearing age with immune-mediated rheumatic diseases, as an unplanned pregnancy during active disease or treatment with…
  • Abstract Number: 0377 • ACR Convergence 2024

    Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis

    Julia Harris1, Leslie Favier2, Emily Fox3, Michael Holland3, Cara Hoffart4, Maria Ibarra3, Jordan Jones4, Susan Parish2, Kara Remick-Erickson2 and Ashley Cooper4, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, 3Children's Mercy Hospital, Kansas City, MO, 4Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: Self-management support (SMS) is one of the key elements of the Chronic Care Model as it is an important aspect of the care for…
  • Abstract Number: 0464 • ACR Convergence 2024

    Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population

    Amir Razmjou1, Rong Guo2, David Elashoff3, Kevin Deane4, Jill Norris5, Marie Feser6, Jennifer Wang1, Ani Shahbazian2 and christina Charles-Schoeman7, 1UCLA, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA Department of Medicine Statistics Core, Los Angeles, 4University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 5Colorado School of Public Health, Denver, CO, 6Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 7UCLA Medical Center, Santa Monica, CA

    Background/Purpose: Rheumatoid arthritis (RA) has a well described pre-clinical state, with a continuum of genetic and environmental risk factors leading to the development of systemic…
  • Abstract Number: 0451 • ACR Convergence 2024

    Macrophages and Interferon Upregulation in Placentas from Patients with Systemic Lupus Erythematosus, Primary Sjögren’s Disease and Antiphospholipid Syndrome

    Juan J. Fierro1, Mirthe Schoots1, Silvia Liefers1, Berber Doornbos-van der Meer2, Gilles Diercks1, Hendrika Bootsma3, Jelmer R. Prins1, Johanna Westra1 and Karina de Leeuw4, 1University Medical Center Groningen, University of Groningen, Groningen, Groningen, Netherlands, 2University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 3Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, 4University Medical Center Groningen, Groningen, Groningen, Netherlands

    Background/Purpose: SLE, primary Sjögren’s disease (pSjD) and APS are systemic rheumatic diseases (SRD) that mainly affect women of childbearing age and have been associated with…
  • Abstract Number: 0394 • ACR Convergence 2024

    Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective

    Francesco Baldo1, Luciana Peixoto2, Remco Erkens3, Greta Rogani3, Claudia Bracaglia4, Dirk Foell5, Marco Gattorno6, Marija Jelusic7, Sebastiaan Vastert3, Rashmi Sinha2 and Francesca Minoia8, and on behalf of the PReS MAS/sJIA Working Party and the Systemic JIA Foundation, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 2Systemic JIA Foundation, Cincinnati, OH, 3University Medical Center Utrecht, Utrecht, Netherlands, 4IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 5University Hospital Muenster, Muenster, Germany, 6IRCCS Giannina Gaslini, Genoa, Italy, 7University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 8Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy

    Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…
  • Abstract Number: 0402 • ACR Convergence 2024

    Reporting of Clinical Features and Outcome Measures in Still’s Disease: A Systematic Literature Review of sJIA and AOSD Cohorts

    Mariana Correia Marques1, Erin Balay-Dustrude2, Claudia Bracaglia3, Marinka Twilt4, Karen Onel5, Simone Appenzeller6, Fatma Dedeoglu7, Esraa Eloseily8, Penelope Martinez Jimenez9, Rebecca Trachtman10, Francesca Minoia11 and Susan Shenoi12, and on behalf of the MAS/sJIA WP of PReS and CARRA sJIA Workgroup, 1National Institutes of Health, Bethesda, MD, 2University of Washington, Seattle, WA, 3IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 4Alberta Children's Hospital, University of Calgary, Cumming School of Medicine, Calgary, Alberta, Canada, Calgary, AB, Canada, 5HSS, New York, NY, 6Department of Orthopedics, Rheumatology and Traumatology. University of Campinas, Campinas, Brazil, 7Boston Children's Hospital, Boston, MA, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Icahn School of Medicine at Mount Sinai- Elmhurst Hospital Center, Rego Park, NY, 10Icahn School of Medicine at Mount Sinai, New York, NY, 11Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, 12Seattle Children's Hospital and Research Center, Mercer Island, WA, WA

    Background/Purpose: Multinational research is essential to globally improve the management of systemic juvenile idiopathic arthritis (sJIA), improve recognition of rare complications like lung disease, and…
  • Abstract Number: 0462 • ACR Convergence 2024

    Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis

    Tate Johnson1, Michael Duryee1, Carlos Hunter1, Punyasha Roul2, Joshua Baker3, grant Cannon4, Beth Wallace5, Paul Monach6, Andreas Reimold7, Gail Kerr8, Isaac Smith9, John Richards10, Katherine Wysham11, Gary Kunkel12, Iris Lee13, Daniel Anderson14, Geoffrey Thiele1, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3University of Pennsylvania, Philadelphia, PA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 6VA Boston Healthcare System, Boston, MA, 7Dallas VA Medical Center, Dallas, TX, 8Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 9Duke University Hospital, Durham, NC, 10Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 11VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 12University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 13Washington University in St Louis, Saint Louis, MO, 14University of Nebraska Medical Center, Durham, NC

    Background/Purpose: Endothelial dysfunction, leading to myocardial inflammation and dysfunction, may drive a heightened risk of heart failure (HF) in people with rheumatoid arthritis (RA). Circulating…
  • Abstract Number: 0446 • ACR Convergence 2024

    Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications

    Kathryn Kompa1 and Vasileios Kyttaris2, 1Beth Israel Deaconess Medical Center, Boston, MA, 2BIDMC, Boston, MA

    Background/Purpose: Methotrexate (MTX) and mycophenolate (MMF) are two common medications for both lupus (SLE) and rheumatoid arthritis (RA). Both medications are contraindicated in pregnancy, necessitating…
  • Abstract Number: 0466 • ACR Convergence 2024

    Inpatient Outcomes of Rheumatoid Arthritis in Hospitalized Patients Using Cannabis: Data from the National Inpatient Sample

    Karun Shrestha1, Prakriti Subedi2, Manoj Ghimire3, Sajana Poudel4, Keerthi Parvathaneni5, Mahmoud Hashim6, Kalpana Ghimire5, Oshna Pandey5, Mohammed Hasan7, Clement Tagoe8 and Liliya Gandrabur9, 1St. Barnabas Hospital Internal Medicine Residency, Bronx, NY, 2St. Barnabas Hospital, Bronx, NY, 3St Barnabas Hospital, BRONX, NY, 4Cook County Health, CHICAGO, NY, 5Department of Internal Medicine, St. Barnabas Hospital, SBH Health System, Bronx, NY 10457, USA, Bronx, NY, 6SBH Health System, New Rochelle, NY, 7Parkview Medical Center, Pueblo, CO, 8Albert Einstein College of Medicine, FRESH MEADOWS, NY, 9SBH Health System, Forest Hills, NY

    Background/Purpose: Despite advancements in rheumatoid arthritis (RA) treatment, effective pain management remains challenging, with many patients also experiencing insomnia, anxiety, and depression. As cannabis legalization…
  • Abstract Number: 0476 • ACR Convergence 2024

    Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients

    Ana Serrano-Combarro1, Belén Atienza-Mateo2, Jesús Alejandro Valero Jaimes3, Marta Pastor-Mena4, Rafael Benito Melero-Gonzalez5, María Martín López6, Santos Castañeda7, Jesús Loarce8, César Antonio Egües Dubuc9, Natalia Mena Vázquez10, Carmen Carrasco-Cubero11, Carolina Perez-Garcia12, Juan M Blanco Madrigal13, Nuria Vegas Revenga14, Lorena Pérez Albadalejo15, Rafaela Ortega-Castro16, Desiree Palma17, Ana Fernández-Ortiz18, Maria López Lasanta19, Marta Garijo Bufort20, Ivette Casafont-Sole21, Andrea García-Valle22, Maria Paz Martinez-Vidal23, Bryan Josué Flores Robles24, EVELIN CERVANTES PEREZ25, Ignacio Brana Abascal26, Sara María Rojas Herrera27, Juan Camilo Sarmiento-Monroy28, Virginia Ruiz-Esquide29, JOSE RAMON LAMUA RIAZUELO30, Uxue Astigarraga-Urquia31, Diego Ferrer32 and Ricardo Blanco-Alonso33, 1Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 3Zumarraga Hospital, Zumarraga, Spain, 4Hospital de Jeréz de la Frontera, Cadiz, Spain, 5CHU Ourense, O Carballino, Spain, 6General University Hospital of Ciudad Real, Ciudad de México, Spain, 7Hospital Universitario de la Princesa, Madrid, Spain, 8Ramón y Cajal University Hospital, Madrid, Madrid, Spain, 9Hospital Universitario de Donostia, Donostia, Pais Vasco, Spain, 10IBIMA, Málaga, Andalucia, Spain, 11Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, 12Hospital del Mar, Barcelona, Spain, 13BASURTO UNIVERSITY HOSPITAL, Bilbao, Spain, 14Hospital Galdakao- Usansolo, Galdakao, Spain, 15Hospital Universitario de Jaén, Jaén, Spain, 16Hospital Reina Sofía, Cordoba, Andalucia, Spain, 17Hospital Rafael Méndez, Lorca, Murcia, Spain, 18Hospital Universitario de Badajoz, Badajoz, Spain, 19Hospital Vall d�Hebron, Barcelona, Spain, 20Hospital de Sagunto, Valencia, Spain, 21Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 22Hospital General Río Carrión, Palencia, Spain, 23Hospital San Juan de Alicante, Alicante, Spain, 24Hospital San Pedro, Logroño, Spain, 25Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, 26Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 27Hospital de Mérida, Badajoz, Spain, 28Hospital Clínic Barcelona, Barcelona, Spain, 29Hospital Clinic de Barcelona, Barcelona, Spain, 30Hospital Universitario del Henares, Madrid, Spain, 31Hospital Universitario de Navarra, Pamplona, Spain, 32Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 33Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Interstitial lung disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA) that determines a worse prognosis, leading the cause of mortality in RA…
  • Abstract Number: 0364 • ACR Convergence 2024

    Exploring 24-Hour Temporal Trends in Symptoms and Treatment of Rheumatic Disease Through Google Search Trends

    Insa Mannstadt1, J. Alex B. Gibbons2 and Bella Mehta3, 1Columbia University VP&S, New York, NY, 2Columbia University Vagelos College of Physicians & Surgeons, New York, NY, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Symptoms of rheumatic diseases such as joint stiffness and pain are known to peak in the early morning hours. In the digital age, tracking…
  • Abstract Number: 0348 • ACR Convergence 2024

    Upadacitinib in Interstitial Lung Disease Associated with Idiopathic Inflammatory Myopathies

    Ting Zhang1, Qiyuan Wang2, Wenjia Sun3, Lei Liu1 and Jing Xue4, 1Zhejiang University, Hangzhou, China (People's Republic), 2Zhejiang Univerisity, Hangzhou, China (People's Republic), 3The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China (People's Republic), 4The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China (People's Republic)

    Background/Purpose: Interstitial lung disease (ILD) is one of the most severe complications in idiopathic inflammatory myopathies (IIM), substantially contributing to the morbidity and mortality. ILD…
  • Abstract Number: 0426 • ACR Convergence 2024

    Quality Improvement Initiative to Increase Contraception Screening and Documentation for Reproductive-Aged Women Prescribed Teratogenic Medications in an Academic Rheumatology Center

    Caroline Siegel1, Avi Mikhaylov1, Emily Wu2, Deanna Jannat-Khah1, Erika Abramson3, Lisa Sammaritano4 and Nancy Pan5, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Rochester, NY, 3Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, Scarsdale, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Rheumatology patients prescribed teratogenic medications often are not prescribed effective contraception. Efforts to improve this important quality indicator are limited by inadequate and poorly…
  • Abstract Number: 0434 • ACR Convergence 2024

    Pregnancy Outcomes of Biosimilars and Non-TNF Inhibitor Biologic Disease-Modifying Antirheumatic Drugs: A Scoping Review

    Vienna Cheng1, Neda Amiri2, Vicki Cheng1, Ursula Ellis3, Jacquelyn J. Cragg1, Mark Harrison1 and Mary A. De Vera1, 1University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, 2University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada, 3University of British Columbia, Woodward Library, Vancouver, BC, Canada

    Background/Purpose: Biosimilar and biologic (b) DMARDs have revolutionized rheumatic disease management in the recent decades. As these drugs become introduced, it is important to understand…
  • « Previous Page
  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology